Brii Biosciences' (HKG:2137) attributable loss narrowed to 148.1 million yuan in the first half from 280.5 million yuan in the year-ago period, according to a Thursday filing with the Hong Kong bourse.
Loss per share at the drug company narrowed to 0.20 yuan from 0.38 yuan a year earlier.
The company's other income fell to 28.1 million yuan from 70.9 million yuan in the prior year.